Supplement Facts Panel Requirements for Gummy Products: A Line-by-Line Compliance Guide

Why Gummy Labels Fail FDA Scrutiny More Often Than Other Formats

Gummy supplements look simple on the shelf. Colorful, chewable, and consumer-friendly — they seem like the easiest product category to bring to market. But from a labeling compliance standpoint, gummies carry a disproportionate number of risk factors that capsules, softgels, and tablets simply do not. FDA warning letters and retail chargebacks in the gummy space frequently trace back not to manufacturing failures, but to label failures that were entirely avoidable.

The core problem is that gummies are a hybrid dosage form. They are regulated as dietary supplements under 21 CFR Part 111, but they are manufactured using food-processing techniques — depositing, cooking, mogul systems, coating, and moisture-controlled curing. That manufacturing reality creates label compliance challenges that standard supplement labeling templates do not account for. A Supplement Facts panel built for a 500 mg capsule will not translate cleanly to a 2-gummy serving of a pectin-based product where the declared nutrients exist against a background of sugars, citric acid, coating agents, and variable moisture levels.

This guide is written for QA managers, facility owners, and production supervisors who need to understand exactly what the FDA expects on a compliant gummy label — and where gummy-specific manufacturing variables create exposure that must be managed at the formulation and documentation level, not just at the design desk.

Supplement Facts Panel: Structure, Serving Size, and the Gummy-Specific Complications

Under 21 CFR Part 101.36, the Supplement Facts panel must list the serving size, the servings per container, and all dietary ingredients at quantitative levels per serving. For gummies, the serving size declaration is almost always expressed as a number of individual pieces — "2 gummies," "1 gummy," or "3 gummies." That piece-count declaration creates a direct link between your label and your manufacturing process: if your deposited gummy weight varies by more than a few percent, the declared nutrient amounts per serving may no longer be accurate.

This is a fundamental gummy-specific compliance risk. In capsule manufacturing, fill weight variation is controlled and tested, but the dosage unit is self-contained. In gummy manufacturing, the depositing process — whether you are running a starch mogul system, a silicone mold line, or a continuous depositor — produces pieces whose finished weight is affected by cooking temperature, sugar concentration, gelatin or pectin bloom strength, moisture during curing, and coating applied post-molding. A finished gummy that exits curing 8 percent lighter than the target weight is delivering less active ingredient per piece than the label declares.

FDA's position under 21 CFR Part 111.75 is clear: you must verify that the finished product meets all label claims before release. That means your batch records must include finished-piece weight data, and your label claims must be supported by potency testing on the finished gummy — not just on the incoming raw material or the premix. For QA teams building their label compliance infrastructure, the following elements of the Supplement Facts panel each require specific manufacturing documentation:

• Serving size (piece count): Must reflect actual consumer use and be consistent with your finished piece weight targets and potency per piece.
• Nutrient amounts per serving: Must be supported by finished-product testing at a frequency consistent with your validation data.
• Percent Daily Values (%DV): Must use the correct reference daily intakes from 21 CFR Part 101.9 and 101.36; errors here are common when label templates are copied across SKUs.
• Other ingredients list: Must declare all non-active ingredients including gelatin or pectin, sweeteners, coloring agents, coating waxes, and citric acid in descending order of predominance by weight.
• Allergen statements: Gelatin sourced from bovine or porcine must be evaluated in the context of your facility's allergen program; certain consumers consider porcine-derived gelatin a religious or dietary concern, and while this is not a regulated allergen under FALCPA, misidentification of the gelatin source is a labeling accuracy issue.

Moisture Loss, Water Activity, and Potency Drift on the Label

One of the most technically demanding label compliance challenges unique to gummy manufacturers is the relationship between moisture content, water activity, and declared potency. After depositing and demolding, gummies undergo a curing phase during which moisture migrates out of the gummy matrix. The rate and total amount of moisture loss depends on your curing room temperature, relative humidity, air circulation, curing time, and the gummy's formulation — particularly whether you are using a gelatin base, a pectin base, or a blend.

Why does this matter for label compliance? Because the declared nutrient amount on your Supplement Facts panel is expressed on a per-serving basis tied to a specific piece count. If your gummy loses more moisture post-curing than your formulation predicted — or if moisture loss continues during shelf life in packaging that provides inadequate water vapor transmission protection — your active ingredient concentration per gram increases while your piece weight decreases. At the same time, certain water-soluble vitamins and active compounds can degrade under the heat and moisture conditions present during cooking and depositing. The net result can be a finished piece that, despite being manufactured to specification, delivers a potency either above or below the label claim depending on which direction the variance runs.

FDA's overage guidance for supplements is not codified as a single rule, but industry practice — and the expectation of investigators reviewing your batch records and testing data — is that you must design your formula with appropriate overages to ensure potency at end of shelf life, and that your label claims must be achievable through the product's expiration date. For gummy QA programs, this requires:

• Establishing water activity (Aw) specifications for your finished gummy with upper and lower limits, not just a nominal target.
• Conducting real-time and accelerated stability studies that include potency testing at multiple time points, with samples held in the actual packaging configuration.
• Documenting the relationship between finished gummy moisture, piece weight, and declared nutrient delivery in your product development records.
• Including water activity and moisture content as release specifications in your Master Manufacturing Record (MMR), not just as process notes.

Investigators reviewing gummy facilities under 21 CFR Part 111 have cited manufacturers specifically for lacking finished-product specifications that address moisture and for releasing product without potency testing that covers the actual dosage unit — the gummy piece — rather than the bulk slurry or premix.

Net Quantity of Contents and Fill Accuracy for Gummy Containers

The net quantity of contents statement on a gummy supplement label is governed by the Fair Packaging and Labeling Act (FPLA) and 21 CFR Part 101.105. For gummy products sold by piece count — "60 gummies," "90 gummies," "120 gummies" — the declared count must match the actual count in every container. This sounds obvious, but gummy filling operations create real accuracy risk that liquid fill or capsule count operations handle differently.

Automated gummy counting systems rely on weight-based counting, optical counting, or a combination. The precision of these systems must be validated for your specific gummy geometry, size, and coating. A coated gummy versus an uncoated gummy of the same base formulation may count differently on the same line. A gummy that clumps during filling due to surface tackiness — a moisture and coating control issue — can produce count errors even on validated equipment. Your filling validation records should demonstrate that your counting system achieves the required accuracy across the product weight and geometry range you are filling.

Net quantity underfill is an FDA enforcement priority across all packaged food and supplement categories. The FDA uses the NIST Handbook 133 methodology when checking fill accuracy during inspections. For gummy products, this means count accuracy must be verified at statistically meaningful sample sizes, and your QA release procedure should include a final count check or a validated weight-per-count verification for each batch. Failing net quantity compliance is not just a regulatory problem — Amazon and major retail buyers conduct their own incoming label verification checks, and a count discrepancy will trigger a chargeback and a compliance hold regardless of your FDA status.

Structure/Function Claims, Disclaimers, and What Gummy Brands Get Wrong

Structure/function claims are among the most visible elements of a gummy supplement label, and they are also among the most frequently cited areas of non-compliance for dietary supplement brands generally. Under 21 CFR Part 101.93, any structure/function claim on a dietary supplement label must be truthful, not misleading, substantiated by competent and reliable scientific evidence, accompanied by the required disclaimer, and notified to FDA within 30 days of first marketing.

For gummy brands specifically, the compliance failures tend to cluster around a few predictable patterns. First, marketing teams adapt claims from the brand's capsule or powder version of the same product without reviewing whether the evidence base applies equally to the gummy format and its delivered potency. If your gummy delivers 200 mg of a botanical extract per serving and your substantiation file was built around studies using 400 mg doses, the claim may not be adequately substantiated at the gummy dose level. Second, gummy brands frequently carry claims that cross from structure/function territory into disease claim territory — particularly in immune, sleep, and cognitive categories — without recognizing that the colorful, consumer-friendly format amplifies scrutiny, not reduces it.

The required disclaimer — "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." — must appear on the same panel as the claim (or with a reference symbol directing the consumer to the panel where it appears), must be in a box, and must be in type no smaller than one-sixteenth of an inch. On gummy packaging where front panel space is often dominated by graphics and flavoring claims, QA and regulatory affairs teams must audit label proofs specifically for disclaimer placement and legibility before approving artwork for print.

Third-party certification programs like NSF's Certified for Sport or NSF's dietary supplement certification require independent review of label claims as part of their audit process. If your facility is pursuing or maintaining NSF GMP certification, your claim substantiation files will be reviewed. Maintaining organized, current substantiation documentation is not just a regulatory best practice — it is an audit readiness requirement that directly affects your certification status and, by extension, your eligibility for retail and Amazon distribution channels that require third-party certification.

Label Review Workflow and Documentation for Gummy Facilities

Regulatory compliance for gummy labels does not end when the label is designed. Under 21 CFR Part 111, your quality system must include procedures for label issuance, reconciliation, and examination — and your label review process should be documented as a formal step in your product launch and label change control procedures.

A compliant label review workflow for a gummy facility should include the following elements, each with documented sign-off:

1. Formulation-to-label reconciliation: Verify that every ingredient in the finished formula is declared in the correct panel (Supplement Facts or Other Ingredients), that all declared amounts are supported by your formulation and testing data, and that no undeclared ingredients are present.
2. Artwork proof review against 21 CFR Part 101 requirements: Check font size, panel placement, net quantity statement, allergen declarations, name and place of business, and disclaimer language and formatting.
3. Structure/function claim review against substantiation files: Confirm every claim on the label has an active substantiation file and that the 30-day FDA notification has been submitted if the product is being marketed for the first time with that claim.
4. Finished-product testing linkage: Confirm that your QC release testing program covers the nutrients and actives declared on the Supplement Facts panel, that specifications are set for the finished gummy piece, and that your test methods are validated or verified for the gummy matrix.
5. Change control documentation: Any revision to an approved label — including font changes, claim revisions, or new flavor variants — must move through your formal change control process with documented regulatory impact assessment before the new label is approved for use.

Gummy manufacturers who invest in a rigorous label review workflow protect themselves on multiple fronts simultaneously: FDA inspection readiness, Amazon listing compliance, retail buyer documentation requests, and third-party certification audits. The label is not a marketing artifact — it is a regulatory document that your quality system is responsible for controlling.